Rebound Phenomenon After Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease 2019 (COVID-19) in High-Risk Persons.

Nischal Ranganath,John C O'Horo,Douglas W Challener,Sidna M Tulledge-Scheitel,Marsha L Pike,Michael O'Brien,Raymund R Razonable,Aditya Shah

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America（2023）

引用 45|浏览11

暂无评分

摘要

In a cohort of 483 high-risk patients treated with nirmatrelvir/ritonavir for COVID-19, 2 patients (0.4%) required hospitalization by day 30. Four patients (0.8%) experienced rebound of symptoms, which were generally mild, at a median of 9 days after treatment, and all resolved without additional COVID-19-directed therapy.

查看译文

关键词

COVID-19,paxlovid,rebound phenomenon,therapeutics

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要